
The Center for Innovative
NeuroTech Advancement
(CINTA) & NeuroTech
Harbor (NTH) Announce
the Cycle 6 Award
Competition

Supported by the NIH
Blueprint MedTech
Incubator Hubs Program



Blueprint MedTech Incubator Hubs

Mission

To accelerate the development of emerging, ground-breaking technologies into first-in-human studies along the path to being commercially viable, clinically focused solutions for disorders involving the nervous system.



- CINTA (Center for Innovative Neurotech Advancement), a program within CIMIT (Steve Schachter, MD as PI and Paolo Bonato, PhD as co-PI from Spaulding Rehabilitation Hospital).
- NTH (NeuroTech Harbor), a partnership between Johns Hopkins University (contact PI - Sri Sarma, PhD) and Howard University (PI - Evaristus Nwulia, MD).




Blueprint MedTech Incubator Hubs

*Final numbers pending

update on July 14
Awards to date: 84

84*

\$60M* **Funding awarded:**



- In addition to funding, provide expert mentoring, oversight, and in-kind resources to innovator teams.
- Support development and de-risking of these groundbreaking technologies to the point of first-in-human testing (i.e., concluding prior to any evaluation of safety or effectiveness).
- By the conclusion of Hub funding, it is anticipated that projects will have secured non-governmental funding or be ready to apply for funding for a companion Translator solicitation from NIH (which support first-in-human evaluations of safety and effectiveness)

 Blueprint MedTech: Translator (UG3/UH3)
 Blueprint Medtech: Small Business Translator (U44)

Information from Previous Cycle Submissions

- One quarter of pre-proposals are from a small business <50 employees, and 2/3 are from non-academic entities
- Of invited full proposals, 1/3 have never proposed to NIH, indicating we have tapped into a new community
- Of invited full proposals, 1/3 will have received funding (Seedling or Optimizer)
- Early-stage projects (Pilot and Seedling) have a reasonable success rate: 1/3 will have advanced to receive Optimizer awards




Principal Investigators (PIs) from academic institutions, industry or non-profit organizations are invited to apply.

Foreign applicants or sub-awards are not allowed. (Note: foreign consultants and vendors are allowed for domestic projects)

Academic PIs must hold a faculty appointment at an institution of higher education or medical center.

Pls from industry or non-academic non-profits are not required to hold a faculty appointment.



5. Proof

of Value

Clinical

Trials

Ongoing planning and discovery takes

place in 4 key domains throughout the

innovation journey. Learn more about

these domains and associated

milestones at gaits.org.

Key Risks

Funding Path

Milestones and Tasks

Is my concept valid?

Thave an idea and there is a clinical need.

EXPLORATORY/ **DEVELOPMENTAL RESEARCH GRANTS**

(e.g., RO1/R21/REACH)

- · Technology concept and intended use formulated
- Technology feasibility studies
- Experimental proof of concept validation

Will my technology work? Is there a motivated customer?

I have a prototype that works as expected and can demonstrate results.

BLUEPRINT MEDTECH INCUBATOR HUB PROJECTS

Blueprintneurotech.org

- · Technology development project plan
- Quality management system design & development
- Prototype development and verification
- · Usability studies to optimize technology
- Technology validation in pre-clinical environment

Will the technology work in humans?

My solution will be ready for first-inhuman studies in 1-2 years or less.

BLUEPRINT MEDTECH TRANSLATOR PROJECTS

UG3/UH3, PAR-21-315: U44, PAR-21-282

- GLP Pre-clinical safety and effectiveness studies
- · GMP pilot production and validation
- IDE or IRB
- · First-in-human safety and effectiveness studies

Resources Available to Investigators listed on the <u>Blueprint MedTech website</u>

Design, Prototyping, Risk Analysis

- Electronics Manufacturing
- Prototype Manufacturing
- Design Optimization and Risk
- Computational Modeling

Bench and Safety Testing

- Electrical Safety
- Electromagnetic Compatibility
- MR Testing
- Software
- Cybersecurity
- Shelf-life Testing

Biocompatibility and Animal Studies

- · Biocompatibility Testing
- Materials characterization and analytical chemistry
- Sterilization testing/validation
- Preclinical Animal Testing (GLP)
- Preclinical Animal Testing (non-GLP)
- Cadaver Testing

Clinical

- · Clinical trial planning
- Biostatistics
- Data Management
- Neuroethics

Resources provided by:

•Hubs CINTA

NTH

Contracts Actuated Medical

PPD CRO

Business Development


- Public-Private Partnerships CRA, MTA
- Entrepreneurship
- Business Development
- Market / User Research
- Commercialization

Regulatory, Compliance, Quality System

- Regulatory Advising
- QMS Quality Management System setup and audits
- GMP Good Manufacturing Practice setup and audits
- Compliance
- Legal Intellectual Property

Update to Cycle 6 Review Process

- Applicants still submit Pre-proposal as initial step
- Selected applicants will be subsequently invited to submit a full application
- Full applications undergo Viability review which now includes a 1- hour interview
- Selected applicants will now receive a 20-week
 Sprinter Award leading up to Deep Dive
- Selected projects will receive an Optimizer Award



Summary of Awards

- Sprinter awards \$100,000 Total Costs
 - Period of performance is 20 weeks
 - Aim to complete milestones and de-risking activities prior to Deep Dive
- Optimizer awards \$1,285,000 Total Costs.
 - The initial anticipated performance period is 12 months, which can be renewed for up to an additional three 12-month periods with Hub and NIH approval.
 - The final aim of Hub optimizer projects should be a prototype ready for first-inhuman studies.
- Hub resources available to complete scope of work
- Mentors are provided at no cost to applicant
- Indirect costs will be determined by your institution's Federally negotiated rate or up to the de minimis rate of 15%.

Summary of Cycle 6 Review Process

Applicants first submit **pre-proposals**, which will undergo review by NIH program scientific staff for eligibility, including mission fit and alignment with program scope. Pre-proposals are submitted through a simple online application form equivalent to about 4 pages (CoLab).

A subset of the applicants who submit pre-proposals will be selected to submit a **full proposal** (approximately 10 pages) which is submitted through the same online application system. Applicants will be invited to a **one-hour interview** to present and discuss their solution.

A subset of applicants who submit full proposals will be selected for a \$100k total cost Sprinter Award aimed to complete steps that derisk the project. During the 20-week performance period, teams will be provided mentor support and access to hub resources.

Sprinter awardees will advance to participate in a 2-3 week "Deep Dive" evaluation, which is the final stage of due diligence review prior to Optimizer Award funding decisions.

Pre-proposal Applications

Applications must focus on a disorder of the nervous system in an area of interest of the **NIH Participating Institutes/Centers for the Blueprint MedTech: Incubator Hubs program**. Applications outside the mission of these participating Institutes/Centers will be not responsive to this solicitation and therefore not advance to full proposal stage.

Contact Institute Program Officer for questions about **mission fit only**, hub staff for other solicitation questions. (https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech/blueprint-medtech-ics-and-contacts)

Participating Centers and Institutes

- National Institute of Biomedical Imaging and Bioengineering (NIBIB),
- National Center for Complementary and Integrative Health (NCCIH),
- National Eye Institute (NEI),
- National Institute on Aging (NIA),
- National Institute on Alcohol Abuse and Alcoholism (NIAAA),
- National Center for Medical Rehabilitation Research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),
- National Institute on Drug Abuse (NIDA),
- National Institute of Dental and Craniofacial Research (NIDCR),
- National Institute of Mental Health (NIMH),
- National Institute of Neurological Disorders and Stroke (NINDS), and
- Office of Behavioral and Social Sciences Research (OBSSR)
- Helping to End Addiction Long-Term (HEAL)

Note: The National Institute of Child Health and Human Development (NICHD) will only accept applications related to the mission of the National Center for Medical Rehabilitation Research.

Pre-Proposal Application Sections

1) Applicant Information

2) Solution Information

- Medical Condition (select from list)
- Technology (select from list)
- Clinical Need & Standard of Care (<250 words)
- Stage of Technical Development (select from list)
- Solution Description (<250 words)
- Supporting Information and/or References Upload 1 page PDF

3) Project Information

- Proposed Sprinter Scope of Work (< 100 words)
- Optimizer Project Duration
- Anticipated Optimizer Scope of Work (<250 words)
- Regulatory Classification (select from list)
- Regulatory Pathway (<150 words)

Applications that will NOT be considered

- Products not regulated by the FDA.
- Fundamental basic/applied research prior to proof of concept.
- Device technologies that do not significantly advance the state of the art (e.g. device technology that proposes minor modifications to FDAapproved/cleared medical device technology)
- Animal model development: all *in vivo* animal models must be wellestablished and characterized, and available to the applicant.
- Projects focused on technologies for functional augmentation of healthy individuals.

Additional Application Information

- If your project addresses a mental health disorder, you are encouraged to provide preliminary data that uses quantitative, objective measures for outcomes. Please incorporate these measures into your proposal.
- No animal studies or human subject research can be performed using Sprinter Award funding.
- Only IRB-exempt or minimal-risk clinical studies can be proposed for Optimizer funding, and only if minimal risk studies can be conducted at Georgia Tech's HomeLab, one of the core resources of the Blueprint Medtech program.
- Hubs cannot support safety or effectiveness studies. Applicants should apply to the Blueprint MedTech Translator NOFOs: UG3/UH3 or U44.

https://cacp.gatech.edu/research/accessibility/HomeLab

NIH Definition of IRB-Exempt Human Subjects Research

https://grants.nih.gov/sites/default/files/exemption_infographic

NIH Exempt Human Subjects Research

2

8 Exemptions

Meets the definition of human subjects research.

Exempt studies involve human subjects research: research involving a living individual about whom data or biospecimens are obtained/used/studied/analyzed through interaction/intervention, or identifiable, private information is used/studied/analyzed/generated

Meets the criteria of one of the following exemptions:

in an educational setting using normal educational practices*

*Cannot include any other procedures, such as collection of clinical data or biospecimens

Exemption 2: uses educational tests, surveys, interviews, or observations of public behavior*

*Limited IRB review may be required.

Exemption 3: benign behavioral interventions in adults*

*Limited IRB review may be required.

Exemption 4: involves the collection/study of data or specimens if publicly available, or recorded such that subjects cannot be identified*

May be identifiable in limited cases. See §46.104(d)(4)(iii) and (iv) Exemption 5: research or demonstration projects designed to study, evaluate, improve, or examine an NIH public benefit or service program

*Applies to projects that NIH itself administers

Exemption 6: taste and food quality evaluations

Exemption 7: storage of identifiable information or biospecimens for secondary research use. *Broad consent* and *limited IRB review* are required

Exemption 8: secondary research use of identifiable information or biospecimens.

Broad consent and limited IRB review are required

For more information see the <u>NIH OER Human Subjects Research website</u>. Send questions/comments to <u>OER-HS@nih.gov</u>.

What is the definition of minimal risk?

Minimal Risk to subjects means that the probability and magnitude of harm or discomfort anticipated in the research are not greater than those ordinarily encountered in daily life or during the performance of routine physical and psychological examinations or tests and that confidentiality is adequately protected. This category includes protocols that pose "no greater than minimal risk" according to federal regulations.

Examples of Minimal Risk are:

- Study poses no more risk than expected in daily life (e.g., blood draw, physical exam, routine psychological testing).
- Electrophysiological studies in healthy subjects or clinical populations (surface recordings such as EEG, ERP, MEG)
- Non-invasive imaging (e.g., MRI and fMRI) in healthy subjects or clinical populations to investigate basic mechanisms of brain function.

https://www.nimh.nih.gov/funding/clinical-research/nimh-guidance-on-risk-based-monitoring

Lessons Learned from Previous Cycle Submissions Common Reasons for Rejection

Mission fit

Not priority area of NIH participating institutes/centers

Stage of Maturity

- Too early (no proof of concept)
- Too advanced (ready for clinical trials; candidate for UG/UH3 or U44)

Team Composition

- Lacking too many critical areas of expertise
- No evidence of clinical collaboration

Impact

- Not significantly different from existing products
- Only marginal impact on clinical condition

Timeline - Part 1

by 11:59 pm ET.



proposal submission system.

completed in a 20-week period

• Webinars and office hours will be available throughout the process.

Timeline - Part 2

Deep Dive

Oct -Nov 2026

Sprinter Awards will proceed to an advanced, interactive "deep dive" review stage that is expected to take two-three weeks, during which applicants will need to commit significant effort to respond to the deep dive inquiries.

Request for Information

Feb- Mar **2027**

Optimizer Awards

Apr-June 2027

Selected teams will prepare Just in time information for funding requests to NIH Estimate of final award decisions and receipt of funding

General Application Information

Applicants should review and be familiar with the program solicitation and FAQs before completing this application.

Solicitation link: https://blueprintneurotech.org/

FAQ link: https://blueprintneurotech.org/faq

Please send questions to <u>info@blueprintneurotech.org</u>.

Sign up for webinar and office hours!

Placeholder for new QR code



Contacts and Additional Resources

Webinar Slides/Schedule: https://www.cimit.org/web/center-for-innovative-neurotech-advancement/events

FAQs: https://blueprintneurotech.org/faq

All application related questions: info@blueprintneurotech.org

Office Hours:

For Scheduling Only - Tina Cavaluzzi <u>tcavaluzzi@jhu.edu</u>

Availability: 15 minute sessions with program leaders


Friday, July 18: 11:30AM - 1PM ET

Monday, July 21: 11:30AM - 1PM ET

Thursday, July 24: 1:30 - 4PM ET

Monday, July 28: 2:30 - 4PM ET

Friday August 1: 11AM - 12:30PM ET



Good Luck!